Fundraising Fox
Jaguar Health
NASDAQ: JAGXSan Francisco, US · Founded 2013 · Delaware corporation · 2 known investors
Find your way into Jaguar Health
Sign up to see every warm intro you have to Jaguar Health
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Jaguar Health team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Jaguar Health is a pharmaceutical company developing crofelemer, including a novel powder for oral solution formulation, for gastrointestinal conditions and rare intestinal failure indications such as microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) in adults and children. It works through its family companies Napo Pharmaceuticals and Napo Therapeutics.
Founders & leadership
Jaguar Health was founded in 2013 by Lisa Conte.
LC
Lisa ConteFounder
CL
Carol LizakExecutive
PC
Pravin ChaturvediExecutive
JW
SM
Serge MartinodExecutive
CT
Charles ThompsonExecutive
Board
Investors · 2
BVCFreportedShanghai · $5M
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$194.1M disclosed across 42 rounds · 2013–2026
▶$2MraisedJul 2026 · 2 investors · PharmaceuticalsRule 506(b)
▶$2MraisedJul 2026 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lisa ConteExecutive Officer, Director
- Carol LizakExecutive Officer
- Steven KingExecutive Officer
- Jonathan WolinExecutive Officer
- James BochnowskiDirector
- John Micek IIIDirector
- Anula JayasuriyaDirector
- Jonathan SiegelDirector
- Pravin ChaturvediExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.8MraisedJul 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$40.8MraisedJul 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lisa ConteExecutive Officer, Director
- Carol LizakExecutive Officer
- Steven KingExecutive Officer
- Jonathan WolinExecutive Officer
- James BochnowskiDirector
- John Micek IIIDirector
- Anula JayasuriyaDirector
- Jonathan SiegelDirector
- Pravin ChaturvediExecutive Officer
- Offering amount
- $40.8M
- Amount sold
- $40.8M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.8MraisedNov 2025 · PharmaceuticalsRule 506(b)
▶$10.8MraisedNov 2025 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carol LizakExecutive Officer
- John Micek IIIDirector
- Jonathan WolinExecutive Officer
- Lisa ConteExecutive Officer, Director
- Anula JayasuriyaDirector
- Pravin ChaturvediExecutive Officer
- Jonathan SiegelDirector
- James BochnowskiDirector
- Steven KingExecutive Officer
- Offering amount
- $10.8M
- Amount sold
- $10.8M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedOct 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$1MraisedOct 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SiegelDirector
- Steven KingExecutive Officer
- James BochnowskiDirector
- Carol LizakExecutive Officer
- John Micek IIIDirector
- Lisa ConteExecutive Officer, Director
- Jonathan WolinExecutive Officer
- Pravin ChaturvediExecutive Officer
- Anula JayasuriyaDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedSep 2025 · 15 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedSep 2025 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Lisa ConteExecutive Officer, Director
- Steven KingExecutive Officer
- Anula JayasuriyaDirector
- Pravin ChaturvediExecutive Officer
- Jonathan WolinExecutive Officer
- Carol LizakExecutive Officer
- James BochnowskiDirector
- John Micek IIIDirector
- Jonathan SiegelDirector
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMay 2025 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedMay 2025 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carol LizakExecutive Officer
- Pravin ChaturvediExecutive Officer
- James BochnowskiDirector
- Lisa ConteExecutive Officer, Director
- John Micek IIIDirector
- Anula JayasuriyaDirector
- Steven KingExecutive Officer
- Jonathan SiegelDirector
- Jonathan WolinExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Sales commissions
- $190.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60KraisedNov 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$60KraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Carol LizakExecutive Officer
- Lisa ConteExecutive Officer, Director, Promoter
- Jonathan B. SiegelDirector
- Jonathan WolinExecutive Officer
- James BochnowskiDirector
- John Micek IIIDirector
- Anula JayasuriyaDirector
- Steven KingExecutive Officer
- Offering amount
- $60K
- Amount sold
- $60K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedMay 2023 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.8MraisedMay 2023 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anula JayasuriyaDirector
- Jonathan B. SiegelDirector
- John Micek IIIDirector
- Steven KingExecutive Officer
- James BochnowskiDirector
- Carol LizakExecutive Officer
- Lisa ConteExecutive Officer, Director, Promoter
- Jonathan WolinExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$7.9Mvaluation at IPOJul 2019 · $2.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updatesfinance.yahoo.com · Aug 2026
Jaguar Health registers 41M shares for resale | JAGX IPO Registration (S-1)stocktitan.net · Jul 2026
Jaguar Health secures $40M equity line, $2M prefs | JAGX 8-K Filingstocktitan.net · Jun 2026Frequently asked questions
- What does Jaguar Health do?
- Jaguar Health is a pharmaceutical company developing crofelemer, including a novel powder for oral solution formulation, for gastrointestinal conditions and rare intestinal failure indications such as microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) in adults and children. It works through its family companies Napo Pharmaceuticals and Napo Therapeutics.
- Who founded Jaguar Health?
- Jaguar Health was founded by Lisa Conte in 2013.
- Who are Jaguar Health's investors?
- Jaguar Health's investors include BVCF, DigitalDx Ventures.
- How much funding has Jaguar Health raised?
- Jaguar Health has disclosed $194.1M raised across 42 rounds.
- Where is Jaguar Health headquartered?
- Jaguar Health is headquartered in San Francisco, US.